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Background. Phaeohyphomycosis is infection caused by dematiaceous, or darkly pigmented, fungi. The spectrum of disease is 
broad, and optimal therapy remains poorly defined. The Mycoses Study Group established an international case registry of patients 
with proven/probable phaeohyphomycosis with the goal of improving the recognition and management of these infections.
Methods. Patients from 18 sites in 3 countries were enrolled from 2009–2015. Cases were categorized as local superficial, local 
deep (pulmonary, sinus, osteoarticular infections), and disseminated infections. End points were clinical response (partial and com-
plete) and all-cause mortality at 30 days and end of follow-up.
Results. Of 99 patients, 32 had local superficial infection, 41 had local deep infection, and 26 had disseminated infection. The 
most common risk factors were corticosteroids, solid organ transplantation, malignancy, and diabetes. Cultures were positive in 
98% of cases. All-cause mortality was 16% at 30 days and 33% at end of follow-up, and 18 of 26 (69%) with dissemination died. 
Itraconazole was most commonly used for local infections, and voriconazole was used for more severe infections, often in combina-
tion with terbinafine or amphotericin B.
Conclusions. Phaeohyphomycosis is an increasingly recognized infection. Culture remains the most frequently used diagnostic 
method. Triazoles are currently the drugs of choice, often combined with other agents. Further studies are needed to develop optimal 
therapies for disseminated infections.
Keywords. dematiaceous fungus; itraconazole; phaeohyphomycosis; voriconazole. 
Phaeohyphomycosis refers to a group of infections caused by 
dematiaceous, or darkly pigmented, fungi from a variety of 
genera [1]. Although uncommon, these infections are increas-
ingly seen in a variety of clinical syndromes in both immu-
nocompromised and normal hosts [2, 3]. Infections due to 
certain species, such as Lomentospora (formerly Scedosporium) 
prolificans, have a very high mortality rate in immunocompro-
mised patients despite aggressive therapy [4–6]. Other species 
(Cladophialophora bantiana, Rhinocladiella mackenziei) have 
been associated with brain abscesses in apparently normal indi-
viduals with similarly high mortality [2].
Dematiaceous fungi are generally found in soil or associated 
with plants and are distributed worldwide. Surveys of outdoor 
air for fungal spores routinely detect these moulds [7]. Some 
species appear to be geographically restricted, such as R. mac-
kenziei, which is primarily seen in patients from the Middle 
East [8]. Dematiaceous fungi are difficult to classify into a sim-
ple framework of pathophysiology because they represent such 
a diverse group of organisms [9].
Optimal therapy for these infections remains uncertain. Data 
from the literature linking treatment and outcomes are sparse, 
with outcomes generally not well documented. Because these 
infections are so uncommon and varied in the fungal genera 
that cause disease, it is very unlikely that a prospective rand-
omized trial will ever be performed. Therefore, the Mycoses 
Study Group established an international case registry of 
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patients with phaeohyphomycosis in order to better define the 
epidemiology, treatment practices, and patient outcomes of 
these infections.
METHODS
Patients
Patients with proven/probable phaeohyphomycosis were 
enrolled from 18 participating sites in the United States, South 
America (Peru), and Australia. Cases were enrolled prospec-
tively from January 1, 2009, through December 31, 2015. 
Criteria for study inclusion included: (1) culture or detection by 
polymerase chain reaction (PCR; performed at individual MSG 
site discretion) of a dematiaceous fungus from a normally ster-
ile site (or bronchoalveolar lavage) or (2) histopathology con-
firming the presence of pigmented fungi in tissue specimens 
and (3) compatible clinical syndrome. This study was approved 
by each site’s institutional review board.
Study Design
Cases were classified as local superficial infections involving 
only skin and subcutaneous tissues; local deep infections that 
included all other localized infections, such as infection of the 
sinuses, eyes, lungs, bones/joints, and other deep tissues; and 
disseminated infections that included fungemia, central nerv-
ous system (CNS) involvement, and disease at ≥2 noncontig-
uous sites. Patients with allergic sino-pulmonary disease were 
excluded. Chromoblastomycosis and mycetoma due to dema-
tiaceous fungi were also included in this study. Although the 
genus Scedosporium includes many species, only S. prolificans 
was considered dematiaceous for the purposes of this study. 
S. prolificans is now placed in a new genus, Lomentospora, and 
will be referred to as L. prolificans for the remainder of this arti-
cle [4].
Clinical data were entered into the Fungiscope database, an 
international global rare fungal infection registry (Fungiscope, 
www.fungiscope.net; www.clinicalsurveys.net). Data included 
demographic information, sites of disease, methods of diag-
nosis, clinical signs and symptoms, underlying diseases and 
predisposing factors, antifungal and/or surgical therapy, and 
clinical outcomes. Primary outcome measures were all-cause 
mortality and clinical response at 30  days post–diagnosis of 
phaeohyphomycosis. Complete response was defined as com-
plete resolution of clinical and radiological findings, partial 
response was defined as improvement in clinical and radio-
logical findings, and failure was evidence of stable disease or 
progression of infection. Secondary outcome measures were 
all-cause mortality and clinical response at end of the follow-up 
period for each patient.
Mycology
Twenty-seven isolates were collected when available and sent 
to one of the investigators (SGR) for susceptibility testing using 
Clinical and Laboratory Standards Institute (CLSI) M38-A2 
methodology [10]. These study isolates were also provided 
to the Centers for Disease Control (CDC) Fungal Reference 
Laboratory (Atlanta, Georgia), where sequencing of the inter-
nal transcribed spacer (ITS) gene of isolates confirmed species 
identification as previously described [11].
Statistical Analysis
Statistical analysis included descriptive statistics (frequencies, 
means, medians) calculated for clinical, laboratory, and demo-
graphic variables. Chi-square analysis was used to compare 
groups.
RESULTS
Demographics
A total of 99 patients (91 proven cases and 8 probable cases) 
with unique infections and complete treatment and outcome 
data were enrolled; there were 59 men and 40 women. The 
mean age at diagnosis was 59 ± 15 years (range, 24–92 years) 
(Table 1). A  total of 62 cases were from the United States, 30 
from Australia, and 7 from Peru. In the United States, 19 cases 
were located in the South, 23 in the Midwest, 13 in the East, and 
7 in the West.
Risk Factors
The most common predisposing factors/comorbidities for 
infection with dematiaceous fungi were corticosteroid use 
(43%) and solid organ transplant (33%), and these were seen 
across all categories of infection (Table  1). Diabetes mellitus 
(24%) was often seen in patients with local superficial infec-
tions. In contrast, malignancy (27%), chemotherapy (22%), and 
neutropenia (22%) were frequent risk factors in patients with 
local deep and disseminated infections. No obvious risk factor 
was found in 10% of cases.
Mycology
Certain fungal genera and species were more likely to cause 
specific syndromes (Table  2). Alternaria, Exophiala, and 
Fonsecaea were commonly associated with local superficial 
infections. Local deep infections were caused by 16 different 
genera, although only 3 (Alternaria, Curvularia, Lomentospora) 
were responsible for over half of these cases (53%). Almost 
all disseminated infections were caused by Lomentospora, 
Cladophialophora, and Verruconis. The most common patho-
gen was L. prolificans, isolated in 20% of all cases.
Diagnosis was confirmed by culture in 97 of 99 (98%) cases. 
Using ITS sequencing, the CDC further identified 5 isolates to 
the species level, 2 unknown isolates were identified, and 1 iso-
late initially identified as Phialophora verrucosa was determined 
to be Pleurostomophora richardsiae. Histopathology showed 
granulomatous inflammation and/or fungal elements in 49 of 
99 (49%) cases. PCR of tissue was positive in only 12 cases, 2 of 
whom had organisms noted on histopathological examination 
but culture showed no growth.
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Results of antifungal susceptibility testing performed on 
16 available isolates (11 isolates either became nonviable or 
did not sporulate) showed that extended spectrum azoles and 
terbinafine were generally the most active antifungal agents 
(Table 3). Other antifungal classes demonstrated limited activ-
ity, and L. prolificans and S. brevicaulis appeared to be resistant 
to all drugs.
Clinical Manifestations and Laboratory Studies
Local Superficial Infections
Among the 32 patients who had local superficial infections, 
solid organ transplantation was the most common risk factor, 
occurring in 53% of patients, followed by corticosteroid use 
(41%) and diabetes mellitus (38%). All patients had skin and 
soft tissue infections, consisting of a variety of papules, plaques, 
nodules, and subcutaneous masses. There were 5 cases of chro-
moblastomycosis caused by F. pedrosoi and 2 cases of mycetoma; 
all of these were from Peru. The lesions were evenly distributed 
between upper (14) and lower (15) extremities, and there were 
2 patients with lesions on the face and 1 with a lesion on the 
trunk. This pattern of distribution suggests direct traumatic 
inoculation as the most common mechanism of infection. Fever 
was present in only 5 patients.
All 32 of these patients were diagnosed by culture of the 
lesions, with 6 isolates having PCR performed to confirm the spe-
cies identification. Histopathology was reported for 23 cases. In 
21 cases, hyphae or fungal elements were seen, and in 8 of these 
granulomas also were noted. One specimen had granulomas 
only, and 1 had neither fungal elements nor granulomas seen.
Local Deep Infections
The local deep infection group was comprised of 41 patients 
who had a variety of clinical syndromes. The most common sites 
of involvement were pulmonary (13 cases), sinuses (11 cases), 
and bone/joint (10 cases). Fever was present in 15 of 41 (37%) 
patients. Twelve of the 13 patients (92%) who had pulmonary 
infection had dyspnea, 10 (77%) had cough, and 2 (15%) had 
Table  1. Demographics and Risk Factors for 99 Patients With 
Phaeohyphomycosis
No. (%)
Total
Local- 
Superficial Local-Deep Disseminated
Demographics (n = 99) (n = 32) (n = 41) (n = 26)
Men 59 (60) 22 (69) 23 (56) 14 (54)
Women 40 (40) 10 (31) 18 (44) 12 (46)
Age, mean, y 59 57 61 57
Range 24–92 32–78 26–92 24–87
Ethnicity
 Caucasian 67 (68) 18 (56) 29 (71) 20 (77)
 Hispanic 14 (14) 9 (28) 4 (10) 1 (4)
 African 7 (7) 1 (3) 4 (10) 2 (8)
 Asian 8 (8) 4 (13) 2 (5) 2 (8)
 Arabic 3 (3) 0 (0) 2 (5) 1 (4)
Risk factor
Stem cell 
transplantation
10 (10) 1 (3) 5 (12) 4 (15)
Graft vs host 
disease
6 (6) 0 (0) 4 (10) 2 (8)
Solid organ 
transplantation
33 (33) 17 (53) 9 (22) 7 (27)
 Heart 2 (2) 1 (3) 1 (2) 0
 Lung 9 (9) 4 (12) 5 (12) 0
 Liver 2 (2) 1 (3) 1 (2) 0
 Kidney 18 (18) 10 (31) 3 (7) 5 (19)
 Pancreas 1 (1) 1 (3) 0 0
 Intestine 1 (1) 0 (0) 0 1 (4)
HIV/AIDS 2 (2) 0 (0) 1 (2) 1 (4)
Chemotherapy 22 (22) 1 (3) 11 (27) 10 (38)
Neutropenia 22 (22) 1 (3) 10 (23) 11 (42)
Corticosteroid use 43 (43) 13 (41) 17 (41) 13 (50)
Malignancy 27 (27) 1 (3) 14 (34) 12 (46)
Other immuno-
suppression
16 (16) 2 (6) 8 (20) 6 (23)
Burn 1 (1) 1 (3) 0 (0) 0
Trauma 10 (10) 3 (9) 6 (15) 1 (4)
Diabetes mellitus 24 (24) 12 (38) 8 (20) 4 (15)
Alcohol abuse 3 (3) 0 (0) 2 (5) 1 (4)
Chronic liver 
disease
4 (4) 2 (6) 2 (5) 0
Chronic renal 
disease
7 (7) 3 (9) 2 (5) 2 (8)
Chronic pulmonary 
disease
13 (13) 4 (12) 8 (20) 1 (4)
No risk factor 10 (10) 5 (16) 3 (7) 2 (8)
Table  2. Fungal Genera Isolated From 99 Patients With 
Phaeohyphomycosis
Genus
No. (%)
Total
Local- 
Superficial Local-Deep Disseminated
(n = 99) (n = 32) (n = 41) (n = 26)
Acrophialophora 1 (1) 1 (2)
Alternaria 12 (12) 6 (17) 6 (14)
Aureobasidium 1 (1) 1 (2)
Biatriospora 1 (1) 1 (3)
Chaetomium 3 (3) 1 (3) 2 (5)
Cladophialophora 5 (5) 5 (18)
Cladosporium 2 (2) 2 (5)
Colletotricum 1 (1) 1 (2)
Curvularia 11 (11) 1 (3) 9 (22) 1 (4)
Exophiala 12 (12) 6 (17) 5 (12) 1 (4)
Exserohilum 4 (4) 2 (6) 2 (5)
Fonsecaea 8 (8) 7 (22) 1 (4)
Lomentospora 20 (20) 8 (19) 12 (43)
Madurella 1 (1) 1 (3)
Medicopsis 2 (2) 2 (6)
Microsphaeropsis 2 (2) 1 (3) 1 (4)
Paraconiothyrium 1 (1) 1 (2)
Phaeoacremonium 3 (3) 2 (6) 1 (2)
Phialophora 2 (2) 2 (6)
Pleurostomaphora 1 (1) 1 (2)
Scopulariopsis 1 (1) 1 (2)
Ulocladium 1 (1) 1 (2)
Verruconis 5 (5) 5 (18)
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pleuritic chest pain; none had hemoptysis. For those patients 
who had invasive sinusitis, 7 (64%) had sinus pain and 6 (55%) 
had facial swelling; only 3 had an eschar seen on sinus endoscopy.
The most common genera causing local deep infection were 
Alternaria, Curvularia, and Lomentospora. Diagnosis was made 
by culture in all but one of the 41 patients; in that patient, PCR 
of sinus tissue revealed Colletotricum gleosporioides. Of the 17 
biopsies that were performed, 15 had fungal hyphae noted and 
3 showed granulomatous inflammation.
Disseminated Infections
Almost all of the 26 patients in the disseminated group had 
some risk factor identified. The 2 patients who had no risk 
factors identified had brain abscesses due to C. bantiana. CNS 
involvement was present in 12 patients, pulmonary infection in 
12, and endocarditis in 4. Fever, observed in 14 (54%) patients, 
was significantly more frequent than in patients with local 
infection (54% vs 27%; P = .01). Nodular rash was observed in 5 
patients and neurologic symptoms in 9 patients. The organism 
most commonly causing disseminated infection was L. prolifi-
cans, with C. bantiana and Verruconis gallopava being the next 
most common.
The 4 cases of endocarditis occurred in women; different spe-
cies were found in each: L. prolificans, V. gallopava, F. pedrosoi, and 
Curvularia lunata. Two of these patients were solid organ trans-
plant recipients and were receiving corticosteroids, but the other 
2 were not immunosuppressed. Blood cultures were positive in 
all cases except for the patient who had F. pedrosoi endocarditis, 
who had an echocardiogram showing a mobile left ventricular veg-
etation and grew the organism from biopsy of a skin lesion. All 
patients had large (>1-cm) vegetations noted on echocardiography.
Primary brain abscess occurred in 6 patients (4 men and 2 
women); 5 were caused by C. bantiana and 1 by V. gallopava. 
One patient had received a stem cell transplant, and 3 had 
received corticosteroids prior to diagnosis. The other 2 patients 
had no risk factors identified.
Culture was positive in 25 of the 26 patients; 1 patient had a 
diagnosis of C. bantiana infection established only by PCR of 
brain tissue. Blood cultures yielded a mold in 13 patients, 12 of 
whom had L. prolificans and 1 had V. gallopava. Of 13 patients 
who had a biopsy performed, histopathology revealed fungal 
elements in 11 and granulomas in 2.
Treatment and Outcomes
Local Superficial Infections
Treatment of the 32 patients who had local superficial infec-
tions was primarily with antifungal drugs (Table 4). In addition, 
6 patients had surgical intervention and 5 underwent cryother-
apy, the latter for chromoblastomycosis. One patient was con-
sidered cured with excision of a skin nodule without antifungal 
therapy. Antifungal regimens varied and were often prolonged; 
median treatment duration was 73  days (range, 1–915  days). 
Itraconazole was given to 13 patients, voriconazole to 9, and 
posaconazole to 10. Ten patients received several drugs sequen-
tially, and 2 received concomitant itraconazole and terbinafine.
The primary outcomes of clinical response and mortality at 
30  days were 79% and 3%, respectively (Table  5). By day 30, 
most had only a partial response. The clinical response at end 
of follow-up was 84%, with 11 patients (34%) showing a partial 
response and 16 (50%) having a complete response. Two patients 
died, but neither death was related to the fungal infection.
Local Deep Infections
Therapy included surgery in 20 of the 41 cases. In only 1 
case (tenosynovitis) was surgery alone curative; all other 
patients received concomitant antifungal therapy. The 
Table 3. Minimum Inhibitory Concentration (µg/mL) for 16 Dematiaceous Fungal Isolates
Organism AmB 5-FC Itra Posa Vori Isavu Caspo Mica Anid Terb
Alternaria spp. 0.5 >64 0.5 ≤0.03 1 2 2 0.5 4 1
Cladophialophora bantiana 8 0.25 0.25 0.125 0.125 0.125 4 4 4 0.03
Curvularia lunata 0.25 >64 1 0.125 4 1 8 8 4 0.06
Curvularia spicifera 1 >64 0.5 0.125 1 8 1 2 8 0.125
Exophiala spp. 2 1 0.25 0.06 0.06 0.5 2 8 4 <0.03
Exophiala oligosperma 1 0.25 0.125 ≤0.03 0.5 2 4 4 2 0.125
Fonsecaea pedrosoi 8 32 0.5 0.25 0.125 0.125 8 >16 16 <0.03
Fonsecaea pedrosoi (#2) 8 4 0.5 0.5 0.5 0.5 2 >16 4 <0.03
Lomentospora prolificans >16 >64 >16 >16 >16 >16 16 >16 8 16
Lomentospora prolificans (#2) >16 >64 >16 >16 >16 >16 16 >16 8 8
Lomentospora prolificans (#3) 16 >64 >16 >16 16 >16 16 >16 4 4
Microsphaeropsis arundinis 0.5 32 ≤0.03 ≤0.03 0.125 0.06 8 8 >16 0.25
Phaeoacremonium sphinctophorum 1 8 4 0.5 0.5 2 16 >16 4 0.25
Pleurostomophora richardsiae 4 4 1 0.5 0.5 0.5 4 >16 1 0.125
Scopulariopsis brevicaulis 16 >64 >16 >16 >16 >16 8 2 2 0.5
Verruconis gallopava 2 2 0.5 0.25 1 16 1 <0.03 <0.03 <0.03
Abbreviations: 5-FC, flucytosine; AmB, amphotericin B; anid, anidulafungin; caspo, caspofungin; isavu, isavuconazole; itra, itraconazole; mica, micafungin; posa, posaconazole; terb, terbin-
afine; vori, voriconazole.
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median duration of antifungal treatment was 50  days (range, 
3–710 days). Voriconazole was used in 26 of 40 (65%) patients, 
12 of whom received this agent in combination with other anti-
fungal drugs, usually lipid formulation amphotericin B.
The primary outcomes of clinical response and mortality at 
30 days were 53% and 12%, respectively. At the end of follow-up, 
the clinical response rate was 68%, with 18 patients (44%) hav-
ing a complete response and 10 (24%), a partial response. These 
rates did not differ between those receiving combination ther-
apy vs monotherapy. At end of follow-up, 13 patients had died; 
4 deaths were attributed to fungal infection.
Disseminated Infections
Sixteen of the 26 patients who had disseminated infection were 
treated with combination antifungal therapy and 10 with mon-
otherapy. The median duration of drug treatment was 61 days 
(range, 2–720  days). Ten patients received 2-drug therapy, 
5 patients received 3-drug therapy, and 1 patient was given 4 
drugs (L-AmB + voriconazole + flucytosine + micafungin) 
concurrently.
Among the endocarditis cases, only the patient who had 
C. lunata infection underwent valve replacement. This patient 
also received posaconazole + terbinafine and was alive at 
5  months. The other surviving patient, who had V.  gallopava 
endocarditis, received voriconazole + terbinafine + anidu-
lafungin for 1 year. The remaining 2 patients received mono-
therapy with voriconazole, and both died. All 6 patients with 
brain abscess received combination therapy with L-AmB + 
voriconazole or posaconazole. Additionally, 1 patient also 
received 5-FC, 1 terbinafine, and 1 5-FC and micafungin. Four 
patients underwent surgery. Only 2 of the 6 patients were alive 
at 3 months.
In disseminated cases, primary outcomes of clinical response 
and mortality at 30 days were 31% and 38%, respectively. At end 
of follow-up, clinical response was seen in 5 of 16 (31%) patients 
who were treated with combination therapy vs 3 of 10 (30%) 
patients who had received monotherapy. Eighteen patients 
(69%) died, with 13 deaths attributed to fungal infection. Eleven 
(69%) patients receiving combination therapy died compared 
with 7 (70%) receiving monotherapy. Patients with L. prolificans 
infection had mortality of 100% compared with 36% for infec-
tion due to other fungi (P < .01), which may reflect the impact 
of underlying disease. At end of follow-up, those with dissemi-
nated infection compared with those with local deep infections 
had significantly worse clinical response, 31% vs 68% (P < .01), 
and mortality, 69% vs 32% (P < .01).
DISCUSSION
Dematiaceous fungi are increasingly important causes of dis-
ease [9]. Numerous species have been implicated in a variety of 
different clinical syndromes [9]. This diversity presents a chal-
lenge to efforts to develop useful, consistent guidelines for man-
agement [12]. The literature contains mostly anecdotal clinical 
reports that are subject to publication bias, making it difficult 
to derive more general recommendations regarding manage-
ment of these infections. This study represents a comprehensive 
attempt to formally study and provide a frame of reference for 
these heterogeneous and often refractory infections.
Table 4. Therapy for Phaeohyphomycosis in 99 Patients
Therapya
No. (%)
Total
Local- 
Superficial Local-Deep Disseminated
(n = 99) (n = 32) (n = 41) (n = 26)
Monotherapy
Lipid AmB 15 (15) 4 (13) 9 (22) 2 (8)
Itraconazole 21 (16) 13 (41) 7 (17) 1 (4)
Voriconazole 32 (32) 9 (28) 14 (34) 9 (35)
Posaconazole 16 (16) 10 (31) 5 (12) 1 (4)
Isavuconazole 2 (2) 1 (3) 1 (2) 0 (0)
Fluconazole 1 (1) 0 (0) 1 (2) 0 (0)
Caspofungin 2 (2) 1 (3) 0 (0) 1 (4)
Micafungin 2 (2) 1 (3) 1 (2) 0 (0)
Terbinafine 1 (1) 1 (3) 0 (0) 0 (0)
Combination therapy
Azole + terbinafine 12 (12) 2 (6) 4 (10) 6 (23)
Azole + AmB 14 (14) 1 (3) 9 (22) 4 (15)
Azole + echinocandin 2 (2) 1 (3) 1 (2) 0 (0)
Azole + 5-FC 1 (1) 0 (0) 0 (0) 1 (4)
AmB + echinocandin 1 (1) 0 (0) 1 (3) 0 (0)
Triple-drug combination 6 (6) 0 (0) 1 (2) 5 (19)
Four-drug combination 1 (1) 0 (0) 0 (0) 1 (4)
Surgery 33 (33) 6 (19) 20 (49) 7 (27)
Cryotherapy 5 (5) 5 (12) 0 (0) 0 (0)
Abbreviations: 5-FC, flucytosine; AmB, amphotericin B; Azole, itraconazole, voriconazole, 
or posaconazole
aSome patients received more than 1 antifungal or combinations of antifungal agents at 
different times.
Table 5. Outcomes of 99 Patients With Phaeohyphomycoses
Outcome
No. (%)
Local-Superficial Local-Deep Disseminated
(n = 32) (n = 41) (n = 26)
30-day response
 Complete 4 (13) 5 (12) 2 (8)
 Partial 21 (66) 17 (41) 6 (23)
 Failure 7 (22) 19 (46) 18 (69)
End-of-follow-up response
 Complete 16 (50) 18 (44) 3 (12)
 Partial 11 (34) 10 (24) 5 (19)
 Failure 5 (16) 13 (32) 18 (69)
Mortality
 30 d 1 (3) 5 (12) 10 (38)
 End of follow-up 2 (6) 13 (32) 18 (69)
 Due to fungal infection 0 (0) 4 (10) 13 (50)
 Follow-up, median (range), d 189 (14–1006) 130 (2–1155) 69 (1–1104)
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The pathogenesis of infections due to dematiaceous fungi is 
not well understood. Superficial infections are generally con-
sidered secondary to local trauma and manifest little tissue 
invasion; disseminated infection is uncommon except in immu-
nocompromised individuals. A  likely candidate virulence fac-
tor for these organisms is melanin, which is present in the cell 
wall of all dematiaceous fungi. In experimental animal models, 
disruption of specific genes involved in melanin production 
leads to markedly reduced virulence [13, 14]. There are several 
mechanisms proposed by which melanin may act as a virulence 
factor, including scavenging free radicals and hypochlorite pro-
duced by phagocytic cells in the oxidative burst, thus preventing 
killing of the organisms [15]. Recently, mutations in a specific 
host gene (CARD9) have been associated with an increased risk 
of developing disseminated infection with certain dematiaceous 
fungi [16]. Additional studies are needed to further elucidate 
genetic susceptibility to these many disparate fungi.
The diagnosis of phaeohyphomycosis, as noted in our study, 
primarily relies on careful examination of growth that appears in 
culture and histopathological examination of tissue specimens. 
Not only the routine hematoxylin and eosin stain, but also the 
Fontana-Masson stain, which is specific to melanin, should be 
used [17]. There are no specific non-culture-based methods 
that are routinely available to aid in the diagnosis of phaeohy-
phomycosis. Available antigen-based tests, such as galactoman-
nan and (1,3)-β-D-glucan assays, have not proved useful and 
were rarely utilized in our registry [18, 19]. PCR of highly con-
served regions of ribosomal DNA has the potential to be a use-
ful technique for identification of dematiaceous organisms [20], 
and ITS and D1/D2 analyses are becoming more available for 
identification of this diverse group of fungi from clinical spec-
imens [21]. Matrix Assisted Laser Desorption/Ionization Time 
of Flight (MALDI-ToF) mass spectroscopy may also become an 
accurate method for dematiaceous mold identification as refer-
ence databases for this technique improve [22, 23].
The European Confederation of Medical Mycology, together 
with the European Society of Clinical Microbiology and 
Infectious Diseases, recently published recommendations for 
therapy of phaeohyphomycosis [12]. These recommendations 
reflect the challenges encountered because of the lack of ran-
domized controlled trial data for these fungal infections. The 
guidelines suggest itraconazole, voriconazole, and posaconazole 
as active drugs, with voriconazole preferred for CNS infection 
and posaconazole utilized for salvage therapy [12]. In our regis-
try, voriconazole was the most commonly used agent, primarily 
because of its in vitro activity, better oral absorption and tolera-
bility, and the accumulated experience with this agent for other 
types of invasive mold infections. Itraconazole is still widely 
used in developing countries, and posaconazole occasionally is 
used for refractory infections. There are limited in vitro data 
and clinical experience for the use of isavuconazole for treating 
phaeohyphomycoses [24, 25]. In our study, isavuconazole was 
used only twice as salvage therapy, with 1 partial response and 
1 failure. Interestingly, duration of therapy was longer in local 
superficial infections than local deep or disseminated disease; 
this finding is possibly due to earlier deaths in patients with 
severe disease.
The guidelines suggest using combination antifungal ther-
apy for CNS and disseminated infection [12], and combina-
tion therapy is often used for more refractory infections [26, 
27]. Voriconazole or posaconazole with terbinafine have been 
used in selected cases of L. prolificans infection based on in vitro 
data showing synergistic activity of terbinafine with these azoles 
and promising, but limited, clinical data. However, we found 
no improvement in outcomes with combination therapy, but 
acknowledge that there were small numbers of patients with 
these more severe infections entered into the registry. Given the 
benign nature of using an extended spectrum triazole with ter-
binafine or an echinocandin, continued use of these agents in 
combination is likely, especially for infection with L. prolificans, 
which generally is resistant in vitro to all antifungals [6].
We have collected a very large database of well-documented 
cases of phaeohyphomycosis derived from diverse clinical sites. 
Our hope is that this report is helpful to clinicians and may spur 
additional efforts to systematically study these uncommon, 
often refractory infections. Therapy will undoubtedly continue 
to evolve and improve as additional clinical data accumulate 
regarding management of specific clinical syndromes.
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